Non-Alcoholic Steatohepatitis (NASH) Pipeline Insight, 2024 Featuring 100+ Companies and 110+ Pipeline Drugs Including Lanifibranor (Inventiva Pharma), MSDC-0602K (Cirius Therapeutics), TERN-501 (Terns Pharma)
02 mai 2024 07h25 HE
|
Research and Markets
Dublin, May 02, 2024 (GLOBE NEWSWIRE) -- The "Non-Alcoholic Steatohepatitis (NASH) - Pipeline Insight, 2024" clinical trials has been added to ResearchAndMarkets.com's offering.This report provides...